Wednesday, January 27, 2016
Novo Nordisk launches Tresiba in the United States.
Long-acting Tresiba U-200 now available for adults living with diabetes.
Tresiba (insulin degludec injection) is a once-daily, long-acting basal insulin.
Tresiba was approved by the U.S. Food and Drug Administration (FDA) in September 2015.
Novo Nordisk is working to secure coverage for Tresiba on U.S. health plans and has secured Lowest Brand Co-pay status on the national formulary for CVS Caremark.
reuters.com
